Free Trial
Paul Choi

Paul Choi Analyst Performance

Biotechnology Analyst at The Goldman Sachs Group

Paul Choi is a stock analyst at The Goldman Sachs Group focused in the medical sector, covering 27 publicly traded companies. Over the past year, Paul Choi has issued 18 stock ratings, including buy, hold, and sell recommendations. While full access to Paul Choi's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Paul Choi's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
49 Last 8 Years
Buy Recommendations
44.90% 22 Buy Ratings
Companies Covered
27 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy44.9%22 ratings
Hold38.8%19 ratings
Sell16.3%7 ratings

Out of 49 total stock ratings issued by Paul Choi at The Goldman Sachs Group, the majority (44.9%) have been Buy recommendations, followed by 38.8% Hold and 16.3% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
88.9% of companies on NASDAQ
24 companies
NYSE
11.1% of companies on NYSE
3 companies

Paul Choi, an analyst at The Goldman Sachs Group, currently covers 27 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
26 companies
96.3%
Energy
1 company
3.7%

Paul Choi of The Goldman Sachs Group specializes in stock coverage within the Medical sector, with additional focus on Energy companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
14 companies
51.9%
PHARMACEUTICAL PREPARATIONS
6 companies
22.2%
MED - DRUGS
4 companies
14.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
3.7%
SOLAR
1 company
3.7%
LARGE CAP PHARMA
1 company
3.7%

Paul Choi's Ratings History at The Goldman Sachs Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
9/25/2025Initiated Coverage$16.59$20.00Neutral
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
9/24/2025Upgrade$14.89Hold
Exelixis, Inc. stock logo
EXEL
Exelixis
9/17/2025Initiated Coverage$39.14$47.00Buy
Amarin Corporation PLC stock logo
AMRN
Amarin
6/25/2025Boost Price Target$15.81$12.00Sell
Urogen Pharma stock logo
URGN
Urogen Pharma
6/13/2025Set Price Target$13.49$16.00Neutral
Urogen Pharma stock logo
URGN
Urogen Pharma
5/22/2025Lower Price Target$3.91$3.00Neutral
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
5/16/2025Boost Price Target$1.07$8.00Buy
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
5/2/2025Lower Price Target$2.87$5.00Neutral
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
4/17/2025Lower Price Target$5.48$21.00Buy
Urogen Pharma stock logo
URGN
Urogen Pharma
4/17/2025Lower Price Target$10.05$16.00Neutral
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
4/17/2025Lower Price Target$4.12$10.00Neutral
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
4/17/2025Lower Price Target$0.84$7.00Buy
Amarin Corporation PLC stock logo
AMRN
Amarin
4/17/2025Lower Price Target$9.08$7.00Sell
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
4/17/2025Lower Price Target$35.24$52.00Buy
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3/10/2025Lower Price Target$4.47$12.00Neutral
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2/13/2025Boost Price Target$147.14$225.00Buy
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2/11/2025Downgrade$13.20$12.00Sell
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2/11/2025Downgrade$7.89$14.00Neutral